AU5305096A - Flow electroporation chamber and method - Google Patents

Flow electroporation chamber and method

Info

Publication number: AU5305096A
Authority: AU; Australia
Prior art keywords: flow path; fluid flow; electrodes; cell; ihp
Prior art date: 1995-03-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU53050/96A

Other languages

English (en)

Inventor

Jesse L. Acker

Peter M. Meserol

Rita C. Prodell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Casi Pharmaceuticals Inc

Original Assignee

Entremed Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-10

Filing date

1996-03-11

Publication date

1996-10-02

1995-03-10 Priority claimed from US08/402,145 external-priority patent/US5720921A/en

1996-03-11 Application filed by Entremed Inc filed Critical Entremed Inc

1996-10-02 Publication of AU5305096A publication Critical patent/AU5305096A/en

Status Abandoned legal-status Critical Current

Links

238000004520 electroporation Methods 0.000 title description 159
238000000034 method Methods 0.000 title description 101
239000012530 fluid Substances 0.000 claims description 55
238000001816 cooling Methods 0.000 claims description 32
239000002245 particle Substances 0.000 claims description 24
230000005684 electric field Effects 0.000 claims description 18
238000004891 communication Methods 0.000 claims description 15
230000001052 transient effect Effects 0.000 claims description 4
239000013013 elastic material Substances 0.000 claims 4
238000009877 rendering Methods 0.000 claims 1
210000004027 cell Anatomy 0.000 description 204
210000003743 erythrocyte Anatomy 0.000 description 188
IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 124
229940068041 phytic acid Drugs 0.000 description 124
IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 123
210000004369 blood Anatomy 0.000 description 112
239000008280 blood Substances 0.000 description 112
229910052760 oxygen Inorganic materials 0.000 description 99
239000001301 oxygen Substances 0.000 description 99
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 98
239000000243 solution Substances 0.000 description 88
108010054147 Hemoglobins Proteins 0.000 description 74
102000001554 Hemoglobins Human genes 0.000 description 74
238000005538 encapsulation Methods 0.000 description 48
239000000725 suspension Substances 0.000 description 45
239000012528 membrane Substances 0.000 description 37
239000006285 cell suspension Substances 0.000 description 29
238000005406 washing Methods 0.000 description 29
230000008569 process Effects 0.000 description 28
238000000926 separation method Methods 0.000 description 28
210000001519 tissue Anatomy 0.000 description 28
239000002699 waste material Substances 0.000 description 27
239000013543 active substance Substances 0.000 description 22
239000011148 porous material Substances 0.000 description 22
239000012637 allosteric effector Substances 0.000 description 19
230000001965 increasing effect Effects 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
210000000170 cell membrane Anatomy 0.000 description 15
230000000694 effects Effects 0.000 description 15
210000002381 plasma Anatomy 0.000 description 15
210000003027 ear inner Anatomy 0.000 description 14
239000000872 buffer Substances 0.000 description 13
230000007423 decrease Effects 0.000 description 13
238000011534 incubation Methods 0.000 description 13
210000000265 leukocyte Anatomy 0.000 description 13
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
210000004072 lung Anatomy 0.000 description 12
230000036961 partial effect Effects 0.000 description 12
238000011282 treatment Methods 0.000 description 12
230000027455 binding Effects 0.000 description 11
238000011109 contamination Methods 0.000 description 11
230000004083 survival effect Effects 0.000 description 11
239000003146 anticoagulant agent Substances 0.000 description 10
229940127219 anticoagulant drug Drugs 0.000 description 10
239000000203 mixture Substances 0.000 description 10
-1 nucleotide triphosphates Chemical class 0.000 description 10
230000003204 osmotic effect Effects 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
230000032258 transport Effects 0.000 description 10
238000010348 incorporation Methods 0.000 description 9
239000000463 material Substances 0.000 description 9
238000006213 oxygenation reaction Methods 0.000 description 9
230000003068 static effect Effects 0.000 description 9
239000000126 substance Substances 0.000 description 9
230000006870 function Effects 0.000 description 8
239000007789 gas Substances 0.000 description 8
238000010438 heat treatment Methods 0.000 description 8
239000007788 liquid Substances 0.000 description 8
230000000717 retained effect Effects 0.000 description 8
229930006000 Sucrose Natural products 0.000 description 7
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
208000007502 anemia Diseases 0.000 description 7
230000008901 benefit Effects 0.000 description 7
230000015556 catabolic process Effects 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
238000009792 diffusion process Methods 0.000 description 7
239000003085 diluting agent Substances 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
239000003792 electrolyte Substances 0.000 description 7
239000011521 glass Substances 0.000 description 7
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 7
150000002632 lipids Chemical class 0.000 description 7
TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 7
238000012545 processing Methods 0.000 description 7
229920006395 saturated elastomer Polymers 0.000 description 7
238000003860 storage Methods 0.000 description 7
239000005720 sucrose Substances 0.000 description 7
238000001356 surgical procedure Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
206010019280 Heart failures Diseases 0.000 description 6
239000000306 component Substances 0.000 description 6
238000000502 dialysis Methods 0.000 description 6
201000010099 disease Diseases 0.000 description 6
239000010931 gold Substances 0.000 description 6
229910052737 gold Inorganic materials 0.000 description 6
238000005534 hematocrit Methods 0.000 description 6
210000004180 plasmocyte Anatomy 0.000 description 6
239000001103 potassium chloride Substances 0.000 description 6
235000011164 potassium chloride Nutrition 0.000 description 6
239000000047 product Substances 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
206010007559 Cardiac failure congestive Diseases 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
210000000601 blood cell Anatomy 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
238000001514 detection method Methods 0.000 description 5
230000002708 enhancing effect Effects 0.000 description 5
239000004417 polycarbonate Substances 0.000 description 5
229920000515 polycarbonate Polymers 0.000 description 5
239000004065 semiconductor Substances 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
108010064719 Oxyhemoglobins Proteins 0.000 description 4
229940088623 biologically active substance Drugs 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
230000008859 change Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000009089 cytolysis Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
235000011180 diphosphates Nutrition 0.000 description 4
239000002502 liposome Substances 0.000 description 4
238000011068 loading method Methods 0.000 description 4
229910001629 magnesium chloride Inorganic materials 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
208000010125 myocardial infarction Diseases 0.000 description 4
239000004800 polyvinyl chloride Substances 0.000 description 4
229920000915 polyvinyl chloride Polymers 0.000 description 4
XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 3
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
208000032843 Hemorrhage Diseases 0.000 description 3
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
206010021143 Hypoxia Diseases 0.000 description 3
206010022562 Intermittent claudication Diseases 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
206010035664 Pneumonia Diseases 0.000 description 3
229920000388 Polyphosphate Polymers 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000003281 allosteric effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229910052797 bismuth Inorganic materials 0.000 description 3
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 3
239000003990 capacitor Substances 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
230000006037 cell lysis Effects 0.000 description 3
230000034994 death Effects 0.000 description 3
238000000151 deposition Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
239000001177 diphosphate Substances 0.000 description 3
238000010494 dissociation reaction Methods 0.000 description 3
230000005593 dissociations Effects 0.000 description 3
210000003617 erythrocyte membrane Anatomy 0.000 description 3
230000004927 fusion Effects 0.000 description 3
208000014674 injury Diseases 0.000 description 3
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
229960000367 inositol Drugs 0.000 description 3
208000021156 intermittent vascular claudication Diseases 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000004033 plastic Substances 0.000 description 3
239000004926 polymethyl methacrylate Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
239000001205 polyphosphate Substances 0.000 description 3
235000011176 polyphosphates Nutrition 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
208000007056 sickle cell anemia Diseases 0.000 description 3
229920002379 silicone rubber Polymers 0.000 description 3
239000004945 silicone rubber Substances 0.000 description 3
230000008961 swelling Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
239000011534 wash buffer Substances 0.000 description 3
INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
208000005223 Alkalosis Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
229920001747 Cellulose diacetate Polymers 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
206010014561 Emphysema Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000018262 Peripheral vascular disease Diseases 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000012190 activator Substances 0.000 description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
239000012503 blood component Substances 0.000 description 2
230000036770 blood supply Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000000919 ceramic Substances 0.000 description 2
230000004087 circulation Effects 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
239000012809 cooling fluid Substances 0.000 description 2
239000000112 cooling gas Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
239000012636 effector Substances 0.000 description 2
229920001971 elastomer Polymers 0.000 description 2
238000005868 electrolysis reaction Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000002360 explosive Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
150000003278 haem Chemical class 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
230000007574 infarction Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
150000004001 inositols Chemical class 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
239000006166 lysate Substances 0.000 description 2
230000002934 lysing effect Effects 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
238000013021 overheating Methods 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000002572 peristaltic effect Effects 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
229920000447 polyanionic polymer Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000005086 pumping Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000005060 rubber Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
XSOKHXFFCGXDJZ-UHFFFAOYSA-N telluride(2-) Chemical compound [Te-2] XSOKHXFFCGXDJZ-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000000287 tissue oxygenation Effects 0.000 description 2
230000008736 traumatic injury Effects 0.000 description 2
238000004804 winding Methods 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
241000370685 Arge Species 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
229910001369 Brass Inorganic materials 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010015287 Erythropenia Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
206010017711 Gangrene Diseases 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
208000036581 Haemorrhagic anaemia Diseases 0.000 description 1
208000032456 Hemorrhagic Shock Diseases 0.000 description 1
206010021113 Hypothermia Diseases 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
CTPQAXVNYGZUAJ-UHFFFAOYSA-N Inositol pentaphosphate Natural products OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O CTPQAXVNYGZUAJ-UHFFFAOYSA-N 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
229910001245 Sb alloy Inorganic materials 0.000 description 1
229910001370 Se alloy Inorganic materials 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
239000007994 TES buffer Substances 0.000 description 1
229910001215 Te alloy Inorganic materials 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
239000007997 Tricine buffer Substances 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
CTPQAXVNYGZUAJ-UYSNGIAKSA-N [(1s,2r,4s,5r)-3-hydroxy-2,4,5,6-tetraphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O CTPQAXVNYGZUAJ-UYSNGIAKSA-N 0.000 description 1
YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000004308 accommodation Effects 0.000 description 1
230000037328 acute stress Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000002340 alkalosis Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
150000001449 anionic compounds Chemical class 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
238000003287 bathing Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000003012 bilayer membrane Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000010951 brass Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
230000005796 circulatory shock Effects 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000009146 cooperative binding Effects 0.000 description 1
208000029039 cyanide poisoning Diseases 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
108010002255 deoxyhemoglobin Proteins 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
235000006694 eating habits Nutrition 0.000 description 1
239000013536 elastomeric material Substances 0.000 description 1
238000010292 electrical insulation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000004880 explosion Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
239000000815 hypotonic solution Substances 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000007373 indentation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910001412 inorganic anion Inorganic materials 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000011810 insulating material Substances 0.000 description 1
210000005061 intracellular organelle Anatomy 0.000 description 1
UETZVSHORCDDTH-UHFFFAOYSA-N iron(2+);hexacyanide Chemical compound [Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] UETZVSHORCDDTH-UHFFFAOYSA-N 0.000 description 1
208000023589 ischemic disease Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
230000004768 organ dysfunction Effects 0.000 description 1
150000002891 organic anions Chemical class 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000000467 phytic acid Substances 0.000 description 1
235000002949 phytic acid Nutrition 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000003672 processing method Methods 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
229910002059 quaternary alloy Inorganic materials 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000011669 selenium Substances 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
235000019832 sodium triphosphate Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000012414 sterilization procedure Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
230000035882 stress Effects 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
230000019432 tissue death Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000012773 waffles Nutrition 0.000 description 1
238000010792 warming Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3623—Means for actively controlling temperature of blood
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3692—Washing or rinsing blood or blood constituents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05D—SYSTEMS FOR CONTROLLING OR REGULATING NON-ELECTRIC VARIABLES
- G05D23/00—Control of temperature
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3616—Batch-type treatment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0429—Red blood cells; Erythrocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
- A61M2205/3382—Upper level detectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3606—General characteristics of the apparatus related to heating or cooling cooled
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3673—General characteristics of the apparatus related to heating or cooling thermo-electric, e.g. Peltier effect, thermocouples, semi-conductors

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Anesthesiology (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Sustainable Development (AREA)
Cell Biology (AREA)
Electromagnetism (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
General Physics & Mathematics (AREA)
Automation & Control Theory (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Electrotherapy Devices (AREA)
External Artificial Organs (AREA)
Apparatuses And Processes For Manufacturing Resistors (AREA)
Glass Compositions (AREA)
Physical Deposition Of Substances That Are Components Of Semiconductor Devices (AREA)

AU53050/96A 1995-03-10 1996-03-11 Flow electroporation chamber and method Abandoned AU5305096A (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US08/402,145 US5720921A (en)	1995-03-10	1995-03-10	Flow electroporation chamber and method
US402145		1995-03-10
US490695P	1995-10-06	1995-10-06
US004906		1995-10-06
PCT/US1996/003211 WO1996028199A1 (fr)	1995-03-10	1996-03-11	Chambre d'electroporation en flux et procede associe

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU30136/00A Division AU754218B2 (en)	1995-03-10	2000-04-27	Flow electroporation chamber and method

Publications (1)

Publication Number	Publication Date
AU5305096A true AU5305096A (en)	1996-10-02

Family

ID=26673634

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU53050/96A Abandoned AU5305096A (en)	1995-03-10	1996-03-11	Flow electroporation chamber and method

Country Status (6)

Country	Link
EP (1)	EP0814855A4 (fr)
JP (2)	JP3859709B2 (fr)
KR (1)	KR19980702848A (fr)
CN (1)	CN1195997A (fr)
AU (1)	AU5305096A (fr)
CA (1)	CA2214800C (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6773669B1 (en)	1995-03-10	2004-08-10	Maxcyte, Inc.	Flow electroporation chamber and method
EP1161270B1 (fr) *	1999-03-17	2007-01-10	Haemonetics Corporation	Systeme de traitement du sang
US7029916B2 (en)	2001-02-21	2006-04-18	Maxcyte, Inc.	Apparatus and method for flow electroporation of biological samples
AU2002326717A1 (en)	2001-08-22	2003-03-10	Maxcyte, Inc.	Apparatus and method for electroporation of biological samples
US7601268B2 (en) *	2003-05-27	2009-10-13	Haemonetics Corporation	Continuous blood filtration and method of use
KR101301929B1 (ko)	2004-05-12	2013-09-02	맥스시티 인코포레이티드	조절된 유동 전기 천공 챔버에 관한 방법 및 장치
ZA200610508B (en) *	2004-06-12	2009-01-28	Digital Bio Technology Co Ltd	Electroporator having an elongated hollow member
WO2006001614A1 (fr) *	2004-06-12	2006-01-05	Digital Bio Technology Co., Ltd.	Appareil d'electroporation muni d'un organe creux allonge
KR101084528B1 (ko) *	2008-04-15	2011-11-18	인비트로겐 싱가포르 피티이. 엘티디.	전기천공 장치용 파이펫 팁
CN101857836B (zh) *	2009-11-10	2013-06-12	昆山文曲生物微***有限公司	一种流式电穿孔装置及***
EP2338356A1 (fr) *	2009-12-23	2011-06-29	Südzucker Aktiengesellschaft Mannheim/Ochsenfurt	Système de réacteur pour électroporation
GB201012521D0 (en)	2010-07-27	2010-09-08	Univ Strathclyde	Integrated perfusion system
CN101928666B (zh) *	2010-07-30	2013-04-03	北京大学	一种流式电穿孔装置及***
JP6862178B2 (ja) *	2013-03-13	2021-04-21	ヌバイラ，インコーポレイテッド	処置のための流体送達システム及び方法
US10316335B2 (en)	2013-03-15	2019-06-11	Maxcyte, Inc.	Methods and compositions for generating stable transfected cells
CN115737104A (zh) *	2015-03-31	2023-03-07	昂科赛克医疗公司	用于改进的基于组织感测的电穿孔的***和方法
CA2982759A1 (fr)	2015-04-13	2016-10-20	Maxcyte, Inc.	Procedes et compositions permettant de modifier l'adn genomique
EP3998335A3 (fr) *	2015-05-08	2022-07-27	Biomagnetic Solutions LLC	Appareil et procédé de séparation de cellules immunomagnétique
WO2017176253A1 (fr) *	2016-04-05	2017-10-12	General Electiric Comapny	Composition de plaquettes activées ayant un taux de facteur de croissance ajustable
JP7466444B2 (ja)	2017-05-14	2024-04-12	パラゲートメディカルリミテッド	埋入可能流体抽出システム
US10435713B2 (en) *	2017-09-30	2019-10-08	Inscripta, Inc.	Flow through electroporation instrumentation
CN108795750A (zh) *	2018-05-28	2018-11-13	深圳先进技术研究院	一种带冷却功能的电穿孔装置
WO2020047504A2 (fr)	2018-08-31	2020-03-05	The Charles Stark Draper Laboratory, Inc.	Procédé et appareil de transfection à haut rendement et à haute efficacité de cellules
CN113260697B (zh) *	2018-12-20	2024-07-09	国立大学法人丰桥技术科学大学	电穿孔装置以及外来物质导入细胞的制造方法
US11071860B2 (en)	2019-02-06	2021-07-27	Oncosec Medical Incorporated	Systems and methods for detecting fault conditions in electroporation therapy
JP7248721B2 (ja) *	2021-02-17	2023-03-29	ゼネラル・エレクトリック・カンパニイ	成長因子レベルを調節可能な活性化血小板組成物
WO2022224803A1 (fr)	2021-04-22	2022-10-27	富士フイルム株式会社	Dispositif de perforation électrique, procédé d'introduction de matériau bioactif, procédé de production de biomatériau issu de tissu, et biomatériau issu de tissu
WO2023223931A1 (fr) *	2022-05-16	2023-11-23	富士フイルム株式会社	Dispositif d'électroporation et procédé d'électroporation

1996
- 1996-03-11 AU AU53050/96A patent/AU5305096A/en not_active Abandoned
- 1996-03-11 CN CN96193177A patent/CN1195997A/zh active Pending
- 1996-03-11 KR KR1019970706255A patent/KR19980702848A/ko not_active Application Discontinuation
- 1996-03-11 CA CA002214800A patent/CA2214800C/fr not_active Expired - Lifetime
- 1996-03-11 EP EP96909619A patent/EP0814855A4/fr not_active Withdrawn
- 1996-03-11 JP JP52774896A patent/JP3859709B2/ja not_active Expired - Lifetime
2006
- 2006-07-25 JP JP2006202504A patent/JP4171755B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2214800A1 (fr)	1996-09-19
JP4171755B2 (ja)	2008-10-29
CA2214800C (fr)	2002-01-22
EP0814855A1 (fr)	1998-01-07
EP0814855A4 (fr)	2002-07-17
KR19980702848A (ko)	1998-08-05
JP3859709B2 (ja)	2006-12-20
JP2007007430A (ja)	2007-01-18
CN1195997A (zh)	1998-10-14
JPH11502133A (ja)	1999-02-23

Legal Events

Date	Code	Title	Description
2000-06-01	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted

Publication	Publication Date	Title
US6074605A (en)	2000-06-13	Flow electroporation chamber and method
US5720921A (en)	1998-02-24	Flow electroporation chamber and method
US6090617A (en)	2000-07-18	Flow electroporation chamber with electrodes having a crystalline metal nitride coating
CA2214800C (fr)	2002-01-22	Chambre d'electroporation en flux et procede associe
US5612207A (en)	1997-03-18	Method and apparatus for encapsulation of biologically-active substances in cells
US6773669B1 (en)	2004-08-10	Flow electroporation chamber and method
US20010001064A1 (en)	2001-05-10	Flow electroporation chamber and methods of use thereof
US4752586A (en)	1988-06-21	Apparatus for encapsulating biological active substances into erythrocytes
CA2892729C (fr)	2017-05-09	Procede de lyse/rescellement et dispositif permettant d'incorporer un ingredient actif, en particulier de l'asparaginase ou de l'inositol hexaphosphate, dans des globules rouges
CA2902061C (fr)	2023-08-08	Dispositifs d'appauvrissement de gaz et d'addition de gaz pour traitement sanguin
JP2005511209A (ja)	2005-04-28	病原体不活性化のために調整された血液成分を提供するための、手動の処理システムおよび方法
EP1456345A2 (fr)	2004-09-15	Appareil et procede d'electroporation d'echantillons biologiques
CA2855065A1 (fr)	2012-05-31	Preservation et stockage electromagnetiques du sang
CA2159005C (fr)	2007-06-19	Methode et appareillage pour l'encapsulation de substances biologiquement actives dans les cellules
AU754218B2 (en)	2002-11-07	Flow electroporation chamber and method
CA2363548A1 (fr)	1996-09-19	Chambre d'electroporation en flux et procede associe
Ropars et al.	1987	[24] Large-scale entrapment of drugs into resealed red blood cells using a continuous-flow dialysis system
Högman et al.	1993	Half‐strength citrate CPD and new additive solutions for improved blood preservation. I. Studies of six experimental solutions
CA1221653A (fr)	1987-05-12	Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus